| Year |
Citation |
Score |
| 2015 |
O'Shaughnessy JA, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J, Krekow L, Holmes F, Vukelja S, Lindquist D, Sedlacek SM, Rivera R, Brooks R, McIntyre K, ... ... Blum JL, et al. Patients with Slowly Proliferative Early Breast Cancer have Low 5-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26041745 DOI: 10.1158/1078-0432.CCR-15-0636 |
0.307 |
|
| 2015 |
Levin MK, Wang K, Yelensky R, Cao Y, Ramos C, Hoke N, Pippen J, Blum JL, Brooks B, Palmer G, Palma N, Balasubramanian S, Ross JS, O'Shaughnessy J. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. Cancer Medicine. PMID 25871911 DOI: 10.1002/Cam4.464 |
0.4 |
|
| 2014 |
Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Gonçalves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M, Lubinski J. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1152-8. PMID 24692579 DOI: 10.1093/annonc/mdu134 |
0.306 |
|
| 2014 |
Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, Neuhausen SL, Karlan B, Kim-Sing C, Huzarski T, Gronwald J, McCuaig J, Senter L, Tung N, Ghadirian P, ... ... Blum JL, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Research and Treatment. 143: 579-86. PMID 24458845 DOI: 10.1007/S10549-013-2823-4 |
0.303 |
|
| 2013 |
Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast (Edinburgh, Scotland). 22: 1087-93. PMID 24095220 DOI: 10.1016/j.breast.2013.08.016 |
0.34 |
|
| 2013 |
Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, ... ... Blum JL, et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 13: 117-30. PMID 23770079 DOI: 10.1016/J.Stem.2013.05.004 |
0.313 |
|
| 2013 |
Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Molecular Cancer Therapeutics. 12: 104-16. PMID 23171949 DOI: 10.1158/1535-7163.Mct-12-0781 |
0.307 |
|
| 2012 |
Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, ... ... Blum JL, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers Cancer Epidemiology Biomarkers and Prevention. 21: 1089-1096. PMID 22564871 DOI: 10.1158/1055-9965.Epi-12-0201 |
0.341 |
|
| 2011 |
Rebbeck TR, Mitra N, Domchek SM, Wan F, Friebel TM, Tran TV, Singer CF, Tea MK, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder CL, Garber JE, et al. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research. 71: 5792-805. PMID 21799032 DOI: 10.1158/0008-5472.Can-11-0773 |
0.311 |
|
| 2011 |
Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, et al. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1032-8. PMID 21393566 DOI: 10.1158/1055-9965.Epi-10-0909 |
0.312 |
|
| 2011 |
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (London, England). 377: 914-23. PMID 21376385 DOI: 10.1016/S0140-6736(11)60070-6 |
0.303 |
|
| 2010 |
Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, ... ... Blum JL, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nature Genetics. 42: 885-92. PMID 20852631 DOI: 10.1038/Ng.669 |
0.318 |
|
| 2010 |
Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, et al. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2958-65. PMID 20479419 DOI: 10.1200/JCO.2009.24.1000 |
0.309 |
|
| 2009 |
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin AK, ... ... Blum JL, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Research : Bcr. 11: R76. PMID 19843326 DOI: 10.1186/Bcr2414 |
0.301 |
|
| 2007 |
Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clinical Breast Cancer. 7: 850-6. PMID 18269774 DOI: 10.3816/CBC.2007.n.049 |
0.324 |
|
| 2006 |
Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4384-90. PMID 16926223 DOI: 10.1200/JCO.2005.05.1383 |
0.303 |
|
| 2006 |
O'Shaughnessy JA, Blum JL. Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer. Clinical Breast Cancer. 7: 42-50. PMID 16764743 DOI: 10.3816/CBC.2006.n.012 |
0.316 |
|
| 2005 |
O'Shaughnessy JA, Clark RS, Blum JL, Mennel RG, Snyder D, Ye Z, Liepa AM, Melemed AS, Yardley DA. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clinical Breast Cancer. 6: 143-9. PMID 16001992 DOI: 10.3816/CBC.2005.n.016 |
0.318 |
|
| 2001 |
Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 12: 605-14. PMID 11432617 |
0.347 |
|
| 2001 |
Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. The Oncologist. 6: 56-64. PMID 11161228 |
0.335 |
|
| 1999 |
Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology. 57: 16-20. PMID 10436412 |
0.347 |
|
| Show low-probability matches. |